Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients.
Saved in:
| Title: | Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients. |
|---|---|
| Authors: | Clement MS; Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark., Ebert EBF; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Meldgaard P; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Sorensen BS; Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark. Electronic address: boesoere@rm.dk. |
| Source: | Clinical lung cancer [Clin Lung Cancer] 2021 Nov; Vol. 22 (6), pp. e870-e877. Date of Electronic Publication: 2021 May 17. |
| Publication Type: | Journal Article; Multicenter Study; Observational Study |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1938-0690 |
|---|---|
| DOI: | 10.1016/j.cllc.2021.05.002 |
